Novo Industri

Michael E. Porter; Michael J. Enright

Case | HBS Case Collection | April 1989 (Revised January 1994)

Novo Industri

by Michael E. Porter and Michael J. Enright

Abstract

Describes the structure of the insulin industry, a treatment for diabetes and Novo's strategy and competitive position in early 1982. The industry is undergoing significant change and Novo must decide how to defend and build its international position. Designed as an early case in global strategy. The class can understand how Novo has competed internationally in the past, how that relates to industry structure, and how industry changes will alter the appropriate way of competing globally. Coalitions of alliances factor into the list of strategic alternatives.

Keywords: Change; Global Strategy; Industry Structures; Alliances; Competitive Strategy; Health Disorders; Pharmaceutical Industry;

Language: English

Format: Print

20 pages

Educators Purchase

Citation:

Porter, Michael E., and Michael J. Enright. "Novo Industri." Harvard Business School Case 389-148, April 1989. (Revised January 1994.)

As the diffusion of value-based health care efforts accelerates globally, the need for interoperable information technology systems that support value-based care is essential. Such systems are needed to facilitate dramatic improvements in patient outcomes and efficiency and, importantly, to end an era in which health IT has entrenched the status quo, perpetuated silos, and blocked reimbursement reform. A value-enabling IT platform must organize data around conditions and must enable integrated practice units to integrate care both within and across health systems. In addition, the electronic health record should be the sole source of costing information so that accurate costs for every encounter can be tracked, aggregated, shared, and used for improvement. This is the next generation of health care IT.

Since its establishment in 2005, Hamburg’s Martini Klinik had single mindedly focused on prostate cancer care with a commitment to measure long-term health outcomes for every patient. A wholly owned subsidiary of the University Hospital Hamburg, Martini Klinik was a “hospital in a hospital” in close proximity to other medical departments and services. By 2019, Martini Klinik had become the largest prostate cancer treatment program in the world with 8,000 outpatient cases and more than 2,500 surgical cases annually. Patients came from all over Germany and from around the world. A new and expanded facility was under construction to have the capacity to manage more patients with prostate cancer.

In this report, the authors synthesize their views on U.S. competitiveness and unveil the findings of the 2019 HBS surveys on U.S. competitiveness. Specifically, this report—built on the survey findings and eight years of prior research on the competitiveness of the United States—highlights a disturbing pattern: despite a decade of steady economic growth since the Great Recession, America has done remarkably little to address underlying structural weaknesses in the country’s economy and society. The nation has squandered the recovery.

Faculty & Research

Novo Industri

Abstract

Citation:

About the Author

More from the Author